person · Reporting owner

Stamoulis Christiana

Disclosed activity across 5 companies

Tapewire entity: 16615
SEC CIK: 0001502917

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cogent Biosciences, Inc.UMRX · Entity 3793	President & C.F.O.	March 28, 2018	March 29, 2018
INCYTE CORPINCY · Entity 3182	EVP & Chief Financial Officer	July 14, 2025	July 16, 2025
Keenova Therapeutics plcNONE · Entity 28960	President and CFO	February 25, 2026	February 27, 2026
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875	SVP, Corp Strategy & Bus Devlp	July 30, 2013	August 01, 2013

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cogent Biosciences, Inc.

Report date March 28, 2018 · Filed March 29, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2025-01-28	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-03-28 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: 25% of the shares vests on January 9, 2016, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2025-04-29	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-03-28 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: 25% of the shares vest on April 30, 2016, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.77 · Expires 2027-10-26	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-03-28 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F3: 25% of the shares vest on October 27, 2018, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2028-03-16	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-03-28 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F4: 25% of the shares vest on March 28, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the shares vests on January 9, 2016, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.

F2: 25% of the shares vest on April 30, 2016, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.

F3: 25% of the shares vest on October 27, 2018, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.

F4: 25% of the shares vest on March 28, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.

INCYTE CORP

Report date July 14, 2025 · Filed July 16, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	116,097	Reported balance After 2025-07-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-07-14 · Tax withholding · Disposed 1,407 · Balance 116,097 F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.
Common StockSEC Table I · non-derivative	Direct	114,652	Reported balance After 2025-07-15 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2025-07-15 · Tax withholding · Disposed 1,445 · Balance 114,652 F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.
Common StockSEC Table I · non-derivative	Direct	125,759	Reported balance After 2025-07-15 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2025-07-15 · Grant · Acquired 11,107 · Balance 125,759 F2: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F3: Including the July 15, 2025 grant, this includes an aggregate of 64,006 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.
Performance SharesSEC Table II · derivative / convertible security · Expires 2028-07-15	Direct	27,769	Reported balance After 2025-07-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-07-15 · Grant · Acquired 27,769 · Balance 27,769 F4: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.25 · Expires 2035-07-14	Direct	24,998	Reported balance After 2025-07-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-07-15 · Grant · Acquired 24,998 · Balance 24,998 F5: The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F3: Including the July 15, 2025 grant, this includes an aggregate of 64,006 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

F4: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F5: The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Keenova Therapeutics plc

Report date February 25, 2026 · Filed February 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	174,181	Reported balance After 2026-02-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-25 · Grant · Acquired 101,262 · Balance 174,181 F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2: The RSUs will vest ratably on each of the first three anniversaries of February 25, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.

F2: The RSUs will vest ratably on each of the first three anniversaries of February 25, 2027.

VERTEX PHARMACEUTICALS INC / MA

Report date July 30, 2013 · Filed August 01, 2013

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $83.36 · Expires 2023-07-29	Direct	27,500	Reported balance After 2013-07-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2013-07-30 · Grant · Acquired 27,500 · Balance 27,500 F1: The option vests in 16 quarterly installments from 07/30/2013.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in 16 quarterly installments from 07/30/2013.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

HOLOGIC INC

Report date April 07, 2026 · Filed April 09, 2026

Section 16 reporting ended · disclosed 2026-04-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-04-07 transaction · row 1 1 source row Row 1 · 2026-04-07 · Disposition to issuer · Disposed 50,526 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.92 · Expires 2027-03-08	Direct	Reported balance After 2026-04-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-07 · Disposition to issuer · Disposed 6,816 · Balance 0 F3: For Footnote (3), see Remarks below.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.44 · Expires 2028-03-14	Direct	Reported balance After 2026-04-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-07 · Disposition to issuer · Disposed 7,551 · Balance 0 F3: For Footnote (3), see Remarks below.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.81 · Expires 2029-03-07	Direct	Reported balance After 2026-04-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-07 · Disposition to issuer · Disposed 6,523 · Balance 0 F3: For Footnote (3), see Remarks below.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.36 · Expires 2030-03-05	Direct	Reported balance After 2026-04-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-04-07 · Disposition to issuer · Disposed 7,322 · Balance 0 F3: For Footnote (3), see Remarks below.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.03 · Expires 2031-03-11	Direct	Reported balance After 2026-04-07 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-04-07 · Disposition to issuer · Disposed 5,055 · Balance 0 F3: For Footnote (3), see Remarks below.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.28 · Expires 2032-03-10	Direct	Reported balance After 2026-04-07 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-04-07 · Disposition to issuer · Disposed 5,293 · Balance 0 F3: For Footnote (3), see Remarks below.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.49 · Expires 2033-03-09	Direct	Reported balance After 2026-04-07 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-04-07 · Disposition to issuer · Disposed 4,210 · Balance 0 F3: For Footnote (3), see Remarks below.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.32 · Expires 2034-03-07	Direct	Reported balance After 2026-04-07 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-04-07 · Disposition to issuer · Disposed 4,536 · Balance 0 F3: For Footnote (3), see Remarks below.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.36 · Expires 2035-02-26	Direct	Reported balance After 2026-04-07 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-04-07 · Disposition to issuer · Disposed 5,535 · Balance 0 F3: For Footnote (3), see Remarks below.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").

F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.

F3: For Footnote (3), see Remarks below.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 20, 2023 Filed Jan 24, 2023 21:00 UTC	INCYTE CORP INCY · Entity 3182	GrantEmployee Stock Option (right to buy) · Derivative	24,515	$0.00 Strike: $83.20	$0.00	Disclosure SEC source: 0001209191-23-004566 · doc4.xml · derivative · entry 2 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,515 Underlying: Common Stock · 24,515 shares Expires 2033-01-19 F3 · derivative.exercise_date: Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 and the remainder vesting monthly over three years. Read SEC document
January 20, 2023 Filed Jan 24, 2023 21:00 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	4,980	$0.00	$0.00	Disclosure SEC source: 0001209191-23-004566 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,639 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on January 20, 2023. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: This includes an aggregate of 65,995 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. The aggregate amount also includes the additional Performance Stock Units earned on January 20, 2023. Read SEC document
July 05, 2022 Filed Jul 6, 2022 20:10 UTC	INCYTE CORP INCY · Entity 3182	Tax withholdingCommon Stock	1,124	$79.25	$89,077.00	Disclosure SEC source: 0001209191-22-041079 · doc4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,659 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2022 RSU Grant, this includes an aggregate of 43,878 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. Read SEC document
July 02, 2022 Filed Jul 6, 2022 20:10 UTC	INCYTE CORP INCY · Entity 3182	GrantEmployee Stock Option (right to buy) · Derivative	23,221	$0.00 Strike: $77.67	$0.00	Disclosure SEC source: 0001209191-22-041079 · doc4.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,221 Underlying: Common Stock · 23,221 shares Expires 2032-07-01 F4 · derivative.exercise_date: Beginning July 2, 2022, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document
July 02, 2022 Filed Jul 6, 2022 20:10 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	17,317	$0.00	$0.00	Disclosure SEC source: 0001209191-22-041079 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,783 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Christina Stamoulis' continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
March 10, 2022 Filed Mar 14, 2022 20:33 UTC	HOLOGIC INC HOLX · Entity 12463	GrantNon-qualified Stock Option (Right to Buy) · Derivative	5,293	$0.00 Strike: $70.28	$0.00	Disclosure SEC source: 0001127602-22-009145 · form4.xml · derivative · entry 2 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,293 Underlying: Common Stock · 5,293 shares Expires 2032-03-10 F3 · derivative.exercise_date: Options become exercisable on the date of the 2023 Annual Meeting of Stockholders. Read SEC document
March 10, 2022 Filed Mar 14, 2022 20:33 UTC	HOLOGIC INC HOLX · Entity 12463	GrantCommon Stock	1,565	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-009145 · form4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,435 F1 · shares: Represents restricted stock units which vest on the date of the 2023 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document
February 11, 2022 Filed Feb 15, 2022 21:21 UTC	INCYTE CORP INCY · Entity 3182	Tax withholdingCommon Stock	331	$66.76	$22,097.56	Disclosure SEC source: 0001209191-22-009777 · doc4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,285 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 47,506 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document
February 11, 2022 Filed Feb 15, 2022 21:21 UTC	INCYTE CORP INCY · Entity 3182	Tax withholdingCommon Stock	846	$66.76	$56,478.96	Disclosure SEC source: 0001209191-22-009777 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,616 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document
January 19, 2022 Filed Jan 21, 2022 21:22 UTC	INCYTE CORP INCY · Entity 3182	GrantEmployee Stock Option (right to buy) · Derivative	15,054	$0.00 Strike: $74.78	$0.00	Disclosure SEC source: 0001209191-22-004425 · doc4.xml · derivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2032-01-18 F1 · derivative.exercise_date: Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2022 and the remainder vesting monthly over three years. Read SEC document
January 01, 2022 Filed Jan 5, 2022 21:19 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	14,463	$0.00	$0.00	Disclosure SEC source: 0001209191-22-001661 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,462 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on December 31, 2025, subject to Christiana Stamoulis's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 51,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
November 19, 2021 Filed Nov 23, 2021 21:22 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	2,355	$0.00	$0.00	Disclosure SEC source: 0001209191-21-066421 · doc4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,999 F2 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 19, 2021. The earned shares will vest on the third anniversary of the July 2, 2021 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in February 2021 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded. F3 · balance_after: Including the Performance Stock Units earned on November 19, 2021, this includes an aggregate of 36,681 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document
November 19, 2021 Filed Nov 23, 2021 21:22 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	379	$0.00	$0.00	Disclosure SEC source: 0001209191-21-066421 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,644 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 19, 2021. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:39 UTC	INCYTE CORP INCY · Entity 3182	GrantEmployee Stock Option (right to buy) · Derivative	15,054	$0.00 Strike: $83.58	$0.00	Disclosure SEC source: 0001209191-21-045822 · doc4.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2031-07-01 F4 · derivative.exercise_date: Beginning July 2, 2021, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:39 UTC	INCYTE CORP INCY · Entity 3182	Tax withholdingCommon Stock	516	$0.00	$0.00	Disclosure SEC source: 0001209191-21-045822 · doc4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,265 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2021 Restricted Stock Unit Grant, this includes an aggregate of 33,947 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:39 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	7,853	$0.00	$0.00	Disclosure SEC source: 0001209191-21-045822 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,781 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Christiana Stamoulis's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
March 11, 2021 Filed Mar 15, 2021 22:20 UTC	HOLOGIC INC HOLX · Entity 12463	GrantNon-qualified Stock Option (Right to Buy) · Derivative	5,055	$0.00 Strike: $71.03	$0.00	Disclosure SEC source: 0001127602-21-010630 · form4.xml · derivative · entry 2 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,055 Underlying: Common Stock · 5,055 shares Expires 2031-03-11 F3 · derivative.exercise_date: Option becomes exercisable on the date of the 2022 Annual Meeting of Stockholders. Read SEC document
March 11, 2021 Filed Mar 15, 2021 22:20 UTC	HOLOGIC INC HOLX · Entity 12463	GrantCommon Stock	1,478	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-21-010630 · form4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,870 F1 · shares: Represents restricted stock units which vest on the date of the 2022 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document
February 11, 2021 Filed Feb 16, 2021 21:40 UTC	INCYTE CORP INCY · Entity 3182	Tax withholdingCommon Stock	1,210	$84.99	$102,837.90	Disclosure SEC source: 0001209191-21-010768 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,611 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 27,759 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document
January 15, 2021 Filed Jan 20, 2021 23:02 UTC	INCYTE CORP INCY · Entity 3182	GrantEmployee Stock Option (right to buy) · Derivative	12,743	$0.00 Strike: $90.56	$0.00	Disclosure SEC source: 0001209191-21-004447 · doc4.xml · derivative · entry 2 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2031-01-14 F3 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document
January 15, 2021 Filed Jan 20, 2021 23:02 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	11,522	$0.00	$0.00	Disclosure SEC source: 0001209191-21-004447 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,821 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 15, 2021, subject to Christiana Stamoulis's continued service with the Issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the January 15, 2021 Restricted Stock Unit Grant, this includes an aggregate of 31,397 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document
November 16, 2020 Filed Nov 18, 2020 21:46 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	1,232	$0.00	$0.00	Disclosure SEC source: 0001209191-20-059139 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,299 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 19,875 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document
November 04, 2020 Filed Nov 6, 2020 21:10 UTC	HOLOGIC INC HOLX · Entity 12463	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	11,146	$0.00 Strike: $22.35	$0.00	Disclosure SEC source: 0001127602-20-028361 · form4.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,146 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan. Read SEC document
November 04, 2020 Filed Nov 6, 2020 21:10 UTC	HOLOGIC INC HOLX · Entity 12463	SaleCommon Stock	11,146	$74.00	$824,804.00	Disclosure SEC source: 0001127602-20-028361 · form4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,392 F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan. Read SEC document
November 04, 2020 Filed Nov 6, 2020 21:10 UTC	HOLOGIC INC HOLX · Entity 12463	Exercise / conversionCommon Stock	11,146	$22.35	$249,113.10	Disclosure SEC source: 0001127602-20-028361 · form4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan. Read SEC document
July 02, 2020 Filed Jul 7, 2020 23:24 UTC	INCYTE CORP INCY · Entity 3182	GrantEmployee Stock Option (right to buy) · Derivative	12,743	$0.00 Strike: $106.47	$0.00	Disclosure SEC source: 0001209191-20-041563 · doc4.xml · derivative · entry 2 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2030-07-01 F3 · derivative.exercise_date: Beginning July 2, 2020, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document
July 02, 2020 Filed Jul 7, 2020 23:24 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	6,661	$0.00	$0.00	Disclosure SEC source: 0001209191-20-041563 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,067 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Christiana Stamoulis's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 2, 2020 Restricted Stock Unit Grant, this includes an aggregate of 18,643 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document
March 05, 2020 Filed Mar 9, 2020 21:08 UTC	HOLOGIC INC HOLX · Entity 12463	GrantNon-qualified Stock Option (Right to Buy) · Derivative	7,322	$0.00 Strike: $47.36	$0.00	Disclosure SEC source: 0001127602-20-009974 · form4.xml · derivative · entry 2 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,322 Underlying: Common Stock · 7,322 shares Expires 2030-03-05 F3 · derivative.exercise_date: Options become exercisable on the date of the 2021 Annual Meeting of Stockholders. Read SEC document
March 05, 2020 Filed Mar 9, 2020 21:08 UTC	HOLOGIC INC HOLX · Entity 12463	GrantCommon Stock	2,217	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-20-009974 · form4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,392 F1 · shares: Represents restricted stock units which vest on the date of the 2021 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document
February 11, 2020 Filed Feb 13, 2020 22:21 UTC	INCYTE CORP INCY · Entity 3182	GrantEmployee Stock Option (right to buy) · Derivative	34,240	$0.00 Strike: $76.14	$0.00	Disclosure SEC source: 0001209191-20-009349 · doc4.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,240 Underlying: Common Stock · 34,240 shares Expires 2030-02-11 F4 · derivative.exercise_date: Beginning February 11, 2020, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document
February 11, 2020 Filed Feb 13, 2020 22:21 UTC	INCYTE CORP INCY · Entity 3182	Tax withholdingCommon Stock	780	$76.14	$59,389.20	Disclosure SEC source: 0001209191-20-009349 · doc4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,089 F2 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F3 · balance_after: Including the February 11, 2020 Restricted Unit Grant, Includes an aggregate of 11,982 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
February 11, 2020 Filed Feb 13, 2020 22:21 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	4,268	$76.14	$324,965.52	Disclosure SEC source: 0001209191-20-009349 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,869 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Ms. Christiana Stamoulis's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
November 22, 2019 Filed Nov 26, 2019 21:10 UTC	HOLOGIC INC HOLX · Entity 12463	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	12,306	$0.00 Strike: $20.01	$0.00	Disclosure SEC source: 0001127602-19-033757 · form4.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,306 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 22, 2019 Filed Nov 26, 2019 21:10 UTC	HOLOGIC INC HOLX · Entity 12463	SaleCommon Stock	12,306	$49.75	$612,223.50	Disclosure SEC source: 0001127602-19-033757 · form4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,175 Read SEC document
November 22, 2019 Filed Nov 26, 2019 21:10 UTC	HOLOGIC INC HOLX · Entity 12463	Exercise / conversionCommon Stock	12,306	$20.01	$246,243.06	Disclosure SEC source: 0001127602-19-033757 · form4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 07, 2019 Filed Mar 11, 2019 20:34 UTC	HOLOGIC INC HOLX · Entity 12463	GrantNon-qualified Stock Option (Right to Buy) · Derivative	6,523	$0.00 Strike: $46.81	$0.00	Disclosure SEC source: 0001127602-19-010817 · form4.xml · derivative · entry 2 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,523 Underlying: Common Stock · 6,523 shares Expires 2029-03-07 F3 · derivative.exercise_date: Options become exercisable on the date of the 2020 Annual Meeting of Stockholders Read SEC document
March 07, 2019 Filed Mar 11, 2019 20:34 UTC	HOLOGIC INC HOLX · Entity 12463	GrantCommon Stock	2,136	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-19-010817 · form4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,175 F1 · shares: Represents restricted stock units which vest on the date of 2020 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document
February 11, 2019 Filed Feb 13, 2019 21:20 UTC	INCYTE CORP INCY · Entity 3182	GrantEmployee Stock Option (right to buy) · Derivative	72,809	$0.00 Strike: $80.21	$0.00	Disclosure SEC source: 0001209191-19-009612 · doc4.xml · derivative · entry 2 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,809 Underlying: Common Stock · 72,809 shares Expires 2029-02-11 F2 · derivative.exercise_date: Beginning February 11, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document
February 11, 2019 Filed Feb 13, 2019 21:20 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	10,285	$80.21	$824,959.85	Disclosure SEC source: 0001209191-19-009612 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,285 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Ms. Christiana Stamoulis's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
November 28, 2018 Filed Nov 30, 2018 21:19 UTC	HOLOGIC INC HOLX · Entity 12463	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	13,257	$0.00 Strike: $17.51	$0.00	Disclosure SEC source: 0001127602-18-034840 · form4.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,257 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan. F3 · derivative.exercise_date: This option became fully vested on January 1, 2013. Read SEC document
November 28, 2018 Filed Nov 30, 2018 21:19 UTC	HOLOGIC INC HOLX · Entity 12463	SaleCommon Stock	13,257	$44.50	$589,949.76	Disclosure SEC source: 0001127602-18-034840 · form4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,039 F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan. F2 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $44.50 to $44.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document
November 28, 2018 Filed Nov 30, 2018 21:19 UTC	HOLOGIC INC HOLX · Entity 12463	Exercise / conversionCommon Stock	13,257	$17.51	$232,130.07	Disclosure SEC source: 0001127602-18-034840 · form4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan. Read SEC document
October 02, 2018 Filed Oct 4, 2018 20:39 UTC	HOLOGIC INC HOLX · Entity 12463	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	30,967	$0.00 Strike: $15.29	$0.00	Disclosure SEC source: 0001127602-18-029589 · form4.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,967 shares Expires 2018-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan. F3 · derivative.exercise_date: This option became fully vested on November 1, 2014. Read SEC document
October 02, 2018 Filed Oct 4, 2018 20:39 UTC	HOLOGIC INC HOLX · Entity 12463	SaleCommon Stock	30,967	$40.70	$1,260,480.77	Disclosure SEC source: 0001127602-18-029589 · form4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,039 F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan. F2 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $40.49 to $40.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document
October 02, 2018 Filed Oct 4, 2018 20:39 UTC	HOLOGIC INC HOLX · Entity 12463	Exercise / conversionCommon Stock	30,967	$15.29	$473,485.43	Disclosure SEC source: 0001127602-18-029589 · form4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing Rule 10b5-1 trading plan. Read SEC document
March 14, 2018 Filed Mar 16, 2018 20:30 UTC	HOLOGIC INC HOLX · Entity 12463	GrantNon-qualified Stock Option (Right to Buy) · Derivative	7,551	$0.00 Strike: $38.44	$0.00	Disclosure SEC source: 0001127602-18-011835 · form4.xml · derivative · entry 2 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,551 Underlying: Common Stock · 7,551 shares Expires 2028-03-14 F3 · derivative.exercise_date: Options become exercisable on the date of the 2019 Annual Meeting of Stockholders. Read SEC document
March 14, 2018 Filed Mar 16, 2018 20:30 UTC	HOLOGIC INC HOLX · Entity 12463	GrantCommon Stock	2,406	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-011835 · form4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,039 F1 · shares: Represents restricted stock units which vest on the date of the 2019 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document
March 08, 2017 Filed Mar 9, 2017 21:38 UTC	HOLOGIC INC HOLX · Entity 12463	GrantNon-qualified Stock Option (Right to Buy) · Derivative	6,816	$0.00 Strike: $41.92	$0.00	Disclosure SEC source: 0001127602-17-011066 · form4.xml · derivative · entry 4 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,816 Underlying: Common Stock · 6,816 shares Expires 2027-03-08 F4 · derivative.exercise_date: Options become exercisable on the date of the 2018 Annual Meeting of Stockholders. Read SEC document
March 08, 2017 Filed Mar 9, 2017 21:38 UTC	HOLOGIC INC HOLX · Entity 12463	Exercise / conversionRestricted Stock Unit Award (Right To Receive) · Derivative	2,427	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-17-011066 · form4.xml · derivative · entry 3 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,427 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: RSUs convert into common stock on a one-for-one basis upon vesting. F2 · price: RSUs convert into common stock on a one-for-one basis upon vesting. F3 · derivative.exercise_date: These RSUs vest and convert into shares of common stock on the date of the 2017 Annual Meeting of Stockholders. F3 · derivative.expiration_date: These RSUs vest and convert into shares of common stock on the date of the 2017 Annual Meeting of Stockholders. Read SEC document
March 08, 2017 Filed Mar 9, 2017 21:38 UTC	HOLOGIC INC HOLX · Entity 12463	Exercise / conversionCommon Stock	2,427	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-17-011066 · form4.xml · nonDerivative · entry 2 Stamoulis Christiana · CIK 0001502917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: RSUs convert into common stock on a one-for-one basis upon vesting. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.